Drugs / IPX056
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00914290 | Apr 2009 → Jan 2010 | multiple sclerosis | Impax Laboratories, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2008-12-11 | Impax Laboratories, LLC | Regulatory Impax Provides Update On Meeting With FDA To Review Phase III Trial Results For IPX056 amneal.com ↗
In the meeting with the FDA, the Company was requested to collect additional longer-term controlled clinical data on the safety and efficacy of IPX056. |
| 2008-08-07 | Impax Laboratories, LLC | Results IMPAX Reports Positive Results in Phase III Trial with IPX056 amneal.com ↗
IPX056, an investigational extended-release formulation of baclofen, has met its clinical endpoints in a Phase III study of spasticity in multiple sclerosis patients. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-04-20 | Impax Laboratories, LLC | Impax Pharmaceuticals Reports Positive Achievements on its Two Leading Brand Product Candidates IPX066 and IPX056 amneal.com ↗ |
| 2008-12-11 | Impax Laboratories, LLC | Impax Provides Update On Meeting With FDA To Review Phase III Trial Results For IPX056 amneal.com ↗ |
| 2008-08-07 | Impax Laboratories, LLC | IMPAX Reports Positive Results in Phase III Trial with IPX056 amneal.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPX056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00914290 ↗ |